CN102459268A - 二氮杂高金刚烷衍生物和其使用方法 - Google Patents

二氮杂高金刚烷衍生物和其使用方法 Download PDF

Info

Publication number
CN102459268A
CN102459268A CN2010800368013A CN201080036801A CN102459268A CN 102459268 A CN102459268 A CN 102459268A CN 2010800368013 A CN2010800368013 A CN 2010800368013A CN 201080036801 A CN201080036801 A CN 201080036801A CN 102459268 A CN102459268 A CN 102459268A
Authority
CN
China
Prior art keywords
undecane
diaza tricyclic
pyridin
tricyclic
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800368013A
Other languages
English (en)
Chinese (zh)
Inventor
M.R.施林普夫
K.B.西皮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
|abbvie|gong Si
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43354879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102459268(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of CN102459268A publication Critical patent/CN102459268A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
CN2010800368013A 2009-06-19 2010-06-18 二氮杂高金刚烷衍生物和其使用方法 Pending CN102459268A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21847909P 2009-06-19 2009-06-19
US61/218479 2009-06-19
PCT/CN2010/000889 WO2010145208A1 (en) 2009-06-19 2010-06-18 Diazahomoadamantane derivatives and methods of use thereof

Publications (1)

Publication Number Publication Date
CN102459268A true CN102459268A (zh) 2012-05-16

Family

ID=43354879

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800368013A Pending CN102459268A (zh) 2009-06-19 2010-06-18 二氮杂高金刚烷衍生物和其使用方法

Country Status (15)

Country Link
US (1) US8846661B2 (https=)
EP (1) EP2443122B1 (https=)
JP (1) JP2012530084A (https=)
KR (1) KR20120044978A (https=)
CN (1) CN102459268A (https=)
AU (1) AU2010262643B2 (https=)
BR (1) BRPI1015043A2 (https=)
CA (1) CA2765466A1 (https=)
IL (2) IL216883A (https=)
MX (1) MX2011014019A (https=)
NZ (1) NZ597511A (https=)
PE (1) PE20121066A1 (https=)
RU (2) RU2015110025A (https=)
SG (1) SG176921A1 (https=)
WO (1) WO2010145208A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971280A (zh) * 2018-02-08 2020-11-20 耶路撒冷希伯来大学伊萨姆研究发展公司 杂芳基化合物、其药物组合物和其治疗用途

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2809028C (en) * 2010-08-20 2019-04-09 Research Triangle Institute Nicotinic receptor compounds
CN103087001A (zh) * 2011-11-03 2013-05-08 南京大学 香草酸的1，3，4-噁二唑衍生物及其制法和用途
WO2014165090A1 (en) * 2013-03-13 2014-10-09 The Broad Institute, Inc. Compounds for the treatment of tuberculosis
RU2552649C1 (ru) * 2013-12-13 2015-06-10 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный университет тонких химических технологий имени М.В. Ломоносова" (МИТХТ им. М.В. Ломоносова) Душистые 5-бензил-1,3-диазаадамантан-6-оны
WO2015103005A1 (en) * 2014-01-03 2015-07-09 Research Institute At Nationwide Children's Hospital Amphiphilic amine compounds and their use as therapeutic agents and nanocarriers
EP3623371A1 (en) 2014-12-16 2020-03-18 Axovant Sciences GmbH Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
CN107847494A (zh) 2015-06-10 2018-03-27 阿考温特科学股份有限公司 作为α7‑烟碱乙酰胆碱受体激动剂的氨基苯并异噁唑化合物
JP2018523707A (ja) 2015-08-12 2018-08-23 アクソバント サイエンシズ ゲーエムベーハー α７−ニコチン性アセチルコリン受容体のアゴニストとしてのジェミナル置換アミノベンゾイソオキサゾール化合物
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
US11407753B2 (en) 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EP3814360B8 (en) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
EP3814345B8 (en) 2018-06-27 2024-10-30 PTC Therapeutics, Inc. Heteroaryl compounds for treating huntington's disease
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
WO2008058096A2 (en) * 2006-11-06 2008-05-15 Abbott Laboratories Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands
WO2008118747A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)
WO2008118743A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ321970A (en) * 1995-11-02 2000-02-28 Neurosearch As Fused tropane-derivatives as neurotransmitter reuptake inhibitors
US6093724A (en) * 1998-08-18 2000-07-25 Ucb, S.A. Muscarinic agonists and antagonists
EP1395257A1 (en) * 2001-06-12 2004-03-10 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
US20050065178A1 (en) * 2003-09-19 2005-03-24 Anwer Basha Substituted diazabicycloakane derivatives
DE602004006767T2 (de) * 2003-09-26 2008-02-07 Astrazeneca Ab Nichtamidnonane
TW200840569A (en) * 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
EP2129672B1 (en) * 2007-03-23 2011-05-18 Abbott Laboratories Azaadamantane ester and carbamate derivatives and methods of use thereof
JP5540099B2 (ja) * 2009-09-14 2014-07-02 スベン ライフ サイエンシズ リミティド ５−ｈｔ４受容体リガンドとしての１，２−ジヒドロ−２−オキソキノリン化合物

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4557865A (en) * 1984-05-07 1985-12-10 Pennwalt Corporation Substituted 4-azatricyclo[4.3.1.13,8 ]undecane compounds
CA2348879A1 (en) * 1998-11-02 2000-05-11 Welfide Corporation Pyrrolidine compound and pharmaceutical use thereof
CN1332726A (zh) * 1998-11-02 2002-01-23 卫福有限公司 吡咯烷化合物及其药物用途
WO2008058096A2 (en) * 2006-11-06 2008-05-15 Abbott Laboratories Azaadamantane derivatives and their uses as nicotinic acetylcholine receptors ligands
WO2008118747A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Amimomethyl azaadamantane derivatives and use thereof as selective modulators of the alpha7- neuronal nicotinic acetylcholine receptor (nnrs)
WO2008118743A1 (en) * 2007-03-23 2008-10-02 Abbott Laboratories Acetamide and carboxamide derivatives of azaadamantane and methods of use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111971280A (zh) * 2018-02-08 2020-11-20 耶路撒冷希伯来大学伊萨姆研究发展公司 杂芳基化合物、其药物组合物和其治疗用途

Also Published As

Publication number Publication date
MX2011014019A (es) 2012-02-22
KR20120044978A (ko) 2012-05-08
IL236830A0 (en) 2015-03-31
PE20121066A1 (es) 2012-09-13
EP2443122A4 (en) 2012-12-19
RU2012101784A (ru) 2013-07-27
JP2012530084A (ja) 2012-11-29
US20100324027A1 (en) 2010-12-23
RU2015110025A (ru) 2015-08-20
AU2010262643A1 (en) 2012-02-02
CA2765466A1 (en) 2010-12-23
BRPI1015043A2 (pt) 2019-07-09
AU2010262643B2 (en) 2015-02-19
SG176921A1 (en) 2012-01-30
EP2443122A1 (en) 2012-04-25
US8846661B2 (en) 2014-09-30
IL216883A (en) 2015-02-26
IL216883A0 (en) 2012-02-29
RU2549551C2 (ru) 2015-04-27
NZ597511A (en) 2014-01-31
EP2443122B1 (en) 2014-03-05
WO2010145208A1 (en) 2010-12-23

Similar Documents

Publication Publication Date Title
CN102459268A (zh) 二氮杂高金刚烷衍生物和其使用方法
AU2014221799B2 (en) Novel pyrazole derivative
CN1946714B (zh) 用作多巴胺d3受体调节剂的氮杂二环(3.1.0)己烷衍生物
AU2021200164B2 (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment
KR102794907B1 (ko) Pde1 억제제로서의 치환된 푸라노피리미딘 화합물
TW200829243A (en) Azaadamantane derivatives and methods of use
CN109661396A (zh) 作为rock抑制剂的螺稠合环状脲
TW200526667A (en) Substituted diazabicycloalkane derivatives
WO2013182972A1 (en) Benzimidazole-proline derivatives
TW200930375A (en) Benzofuropyrimidinones
CN103145711A (zh) 氮杂金刚烷酯和氨基甲酸酯衍生物及其使用方法
CN102690265A (zh) 4-取代的氮杂金刚烷衍生物及其使用方法
KR102640696B1 (ko) Pde7 억제제로서 치환된 벤즈옥사졸 및 벤조푸란 화합물
CN102958932A (zh) 5-ht受体调节剂及其使用方法
CN101641356B (zh) 氮杂金刚烷的乙酰胺和甲酰胺衍生物及其使用方法
WO2020007964A1 (en) 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
AU2015202090A1 (en) Diazahomoadamantane derivatives and methods of use thereof
CN101238125A (zh) 5-吡啶基-1-氮杂双环[3.2.1]辛烷衍生物，其制备方法及其在药物中的应用
OA19667A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
HK40036192B (en) Substituted furanopyrimidine compounds as pde1 inhibitors
HK40036192A (en) Substituted furanopyrimidine compounds as pde1 inhibitors
OA20303A (en) Benzodiazepine derivatives, compositions, and methods for treating cognitive impairment.
CN101568541A (zh) 螺环氮杂金刚烷衍生物和使用方法
HK1135972B (en) 4-substituted azaadamantane derivatives and methods of use thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: ABBVIE COMPANY

Free format text: FORMER OWNER: ABBOTT GMBH. + CO. KG

Effective date: 20130620

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20130620

Address after: Illinois State

Applicant after: |ABBVIE|Gong Si

Address before: Illinois State

Applicant before: Abbott GmbH. & Co. Kg

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516